Evidence map›Paper›PMID 35116279›Full record

ArticleTranslational cancer research2021

Simultaneous high PD-L1 and low VEGFR2 expression is associated with better overall survival in rectal cancer.

Yun Ding, Yuanyuan Fu, Wei Wei, Weibin Huang, Zhuojun Zheng, Dachuan Zhang, Jiajia He, Xiao Zheng, Qi Wang, Yingting Liu and 2 more

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Translational cancer research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Yun DingDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Yuanyuan FuDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Wei WeiDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Weibin HuangDepartment of Vascular Surgery, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Zhuojun ZhengDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Dachuan ZhangDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Jiajia HeDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Xiao ZhengDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Qi WangDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Yingting LiuDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Wendong GuDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Jingting JiangDepartment of Tumor Biological Treatment, The Third Affiliated Hospital of Soochow University, Changzhou, China.
Soochow University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe aim of the present study was to analyze the association of programmed cell death-ligand 1 (PD-L1) and vascular endothelial growth factor receptor 2 (VEGFR2) expression levels with clinicopathological characteristics and survival to provide a treatment strategy for rectal cancer.

methodsImmunohistochemical staining of VEGFR2 and PD-L1 was carried out, and the association of PD-L1 and VEGFR2 expression levels with clinicopathological characteristics and survival were investigated in 77 pair-matched rectal cancer patients.

resultsPD-L1 and VEGFR2 expression levels in surgical tumor tissues were higher than those in paired adjacent normal tissues, respectively (both P<0.05). The results of the 5-year overall survival (OS) analysis showed that patients with low VEGFR2 expression (66.7%

conclusionsThe results indicated that tumor PD-L1 and VEGFR2 expression levels were associated with OS, and the combination of tumor PD-L1 and VEGFR2 levels might be an independent prognostic factor in rectal cancer.

Indexed as

overall survival (OS)Programmed cell death-ligand 1 (PD-L1)rectal cancervascular endothelial growth factor receptor 2 (VEGFR2)

Identifiers

PMID35116279
PMCPMC8797419
OpenAlexW3127738308

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.